X-Linked Retinitis Pigmentosa Investigative Gene Therapy is Looking Promising
source: pixabay.com

X-Linked Retinitis Pigmentosa Investigative Gene Therapy is Looking Promising

Janssen Pharmaceuticals has an ongoing Phase 1/2 clinical trial for the inherited retinal disease X-linked retinitis pigmentosa (XLRP). They are investigating an adeno-associated gene therapy called RPGR as a therapeutic…

Continue Reading X-Linked Retinitis Pigmentosa Investigative Gene Therapy is Looking Promising

Enrollment Completed in Achromatopsia and Retinitis Pigmentosa Clinical Trials

ACHM and XLRP Achromatopsia (ACHM) is a rare, inherited retinal disease which causes impaired cone photoreceptor function. Patients experience light sensitivity so extreme that it can cause blindness during the…

Continue Reading Enrollment Completed in Achromatopsia and Retinitis Pigmentosa Clinical Trials